Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...
Zacks Investment Research on MSN3d
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 ApprovalDexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the ...
DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost ...
Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...
6don MSN
In a new study in the journal Diabetes Technology & Therapeutics (DTT), investigators evaluated the accuracy of the 15.5-day ...
Dexcom (Nadsaq:DXCM) announced today that it launched a new multi-region report evaluating type 2 diabetes treatments.
This could affect the approval of the company’s upcoming 15-day G7 continuous glucose monitor (CGM). The letter cited multiple violations, including the failure to submit a premarket ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback